Head-to-head evidence
Diazepam (Valtoco) vs Staccato Alprazolam
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: GABA-A receptor · full Epilepsy pipeline
Diazepam (Valtoco)
Marketed by Neurelis, Inc.
NCT02721069 · Phase 3 · completed
The study was open-label, nonrandomized, and had no placebo or active comparator, so it provides uncontrolled safety and treatment-exposure information rather than comparative evidence of effectiveness. Its primary endpoint was the number of participants receiving NRL-1 over 12 months, not a hard clinical seizure outcome, and no formal primary-endpoint comparison was applicable.
Next expected readout: December 2026 · NCT06346262 (registry estimate)
Staccato Alprazolam
Developed by UCB
NCT03478982 · Phase 2 · completed
The study randomized participants to Staccato alprazolam or matching placebo and was described as quadruple-blind, with 156 participants enrolled and 38, 38, and 40 participants in the evaluable 1.0-mg, 2.0-mg, and placebo groups, respectively. Its primary clinical endpoint—seizure cessation within 2 minutes without recurrence for 2 hours—was statistically significantly better with both alprazolam doses than with placebo.
Next expected readout: October 2026 · NCT05077904 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Diazepam (Valtoco)'s landscape · Staccato Alprazolam's landscape